Showing 59 results
- https://www.novartis.com/news/media-library/about-erenumab-amg-334
- https://www.novartis.com/news/media-library/erenumab-amg-334-key-clinical-trials-numbers
- https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-aimovig-erenumab-prevention-migraineIf approved, Aimovig®(erenumab) is expected to be the first and only available therapy designed specifically for migraine prevention in the EU Positive opinion based on robust data package…
- https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-fda-approval-aimovigtm-erenumab-novel-treatment-developed-specifically-migraine-preventionMigraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-…
- https://www.novartis.com/news/media-releases/novartis-achieves-important-regulatory-milestone-amg-334-erenumab-migraine-prevention-ema-filing-acceptanceAMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance Filing is supported by a comprehensive clinical…
- https://www.novartis.com/news/media-releases/novartis-expands-global-collaboration-amgen-commercialize-first-class-amg-334-erenumab-program-migraine-prevention-us-and-canadaNovartis and Amgen to co-commercialize AMG 334 (erenumab) in the US; Novartis to gain exclusive rights in Canada Novartis retains commercial rights in rest of world; Amgen retains commercial…
- https://www.novartis.com/news/media-releases/novartis-presents-new-data-demonstrating-long-term-efficacy-safety-and-tolerability-aimovig-erenumab-patients-chronic-and-episodic-migraineResults from a one-year study of efficacy and safety of Aimovig in chronic migraine and data from a three-year analysis assessing safety and tolerability of Aimovig in episodic migraine will be…
- https://www.novartis.com/news/media-releases/novartis-presents-data-demonstrating-efficacy-amg-334-erenumab-migraine-prevention-american-headache-society-annual-meetingData from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month AMG 334 (erenumab)…
- https://www.novartis.com/news/media-releases/novartis-presents-first-its-kind-evidence-aan-reinforcing-robust-and-consistent-efficacy-aimovigtm-erenumab-migraine-patients-multiple-treatment-failuresThe LIBERTY trial studied patients with episodic migraine who had failed 2 to 4 prior treatments, a uniquely difficult-to-treat population often excluded from migraine prevention trials …
- https://www.novartis.com/news/media-releases/novartis-announces-new-publication-cephalalgia-data-showcasing-superior-tolerability-and-efficacy-aimovig-erenumab-compared-topiramate-migraine-preventionHER-MES, a Phase IV study, is the first and only randomized, double blind, head-to-head study that compares an antibody targeting the CGRP pathway, Aimovig® (erenumab), with an oral prophylactic…